PARParadigm Biopharmaceuticals Limited

PAR Stock Price, Valuation & Chart | Paradigm Biopharmaceuticals Limited

Compare

$0.200+0.03 (+14.29%)

At close · 24 Aug 2026, 06:11 am

Sector: Healthcare Industry: Biotechnology PAR intrinsic value Is PAR overvalued or undervalued Website

Overview Financials Dividends Ratios

PAR Historical price chart

PAR Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization119.84M

PE Ratio-2.24

EPS-0.09

Trading Volume8.24M

Today's High/Low0.2/0.17

Dividend Yield0.00

52 Week High/Low0.47/0.14

Shares Outstanding599.19M

PAR Financial Statement

PAR Analyst ratings

Buy

Strong buy

Buy

Hold

Sell

Strong sell

Based on 1 analyst giving stock ratings to PAR in the past 3 months.

PAR Analysis & performance metrics

PAR Company profile

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers…

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was…

PAR Management team

Name

Position

Beverley Huttmann

Commercial Head

Paul John Rennie BSc, Grad Dip, MBM, MSTC

Founder, MD & Executive Chairman

Abby Macnish Niven B.Com., B.Sc., C.F.A.CFO

Company Secretary & Chief Financial Officer

Michelle Coffey

Global Head of Regulatory Affairs

Mukesh Ahuja

Global Clinical Head of OA

Simon WhiteCTO

Director of Investor Relations

Michael Imperiale

Global Head of Drug Safety & MPS

Ravi Krishnan

Chief Scientific Officer

Name

Position

Beverley Huttmann

Commercial Head

Paul John Rennie BSc, Grad Dip, MBM, MSTC

Founder, MD & Executive Chairman

Abby Macnish Niven B.Com., B.Sc., C.F.A.CFO

Company Secretary & Chief Financial Officer

Michelle Coffey

Global Head of Regulatory Affairs

Mukesh Ahuja

Global Clinical Head of OA

Simon WhiteCTO

Director of Investor Relations

Michael Imperiale

Global Head of Drug Safety & MPS

Ravi Krishnan

Chief Scientific Officer

Management Team

Beverley Huttmann

Commercial Head

Paul John Rennie BSc, Grad Dip, MBM, MSTC

Founder, MD & Executive Chairman

Abby Macnish Niven B.Com., B.Sc., C.F.A.CFO

Company Secretary & Chief Financial Officer

Michelle Coffey

Global Head of Regulatory Affairs

Mukesh Ahuja

Global Clinical Head of OA

Simon WhiteCTO

Director of Investor Relations

Michael Imperiale

Global Head of Drug Safety & MPS

Ravi Krishnan

Chief Scientific Officer

Management

Beverley Huttmann

Commercial Head

Paul John Rennie BSc, Grad Dip, MBM, MSTC

Founder, MD & Executive Chairman

Abby Macnish Niven B.Com., B.Sc., C.F.A.CFO

Company Secretary & Chief Financial Officer

Michelle Coffey

Global Head of Regulatory Affairs

Mukesh Ahuja

Global Clinical Head of OA

Simon WhiteCTO

Director of Investor Relations

Michael Imperiale

Global Head of Drug Safety & MPS

Ravi Krishnan

Chief Scientific Officer

Total 8 executives

PAR Frequently asked questions

What is Paradigm Biopharmaceuticals Limited (PAR) Stock Price?

Current stock price of Paradigm Biopharmaceuticals Limited (PAR) stock is $0.200. The stock price is +14.29% higher in the session. The intraday range can be seen from this page. Volume of Paradigm Biopharmaceuticals Limited (PAR) stock is 8.24M.

Last updated at 24 Aug 2026, 06:11 am.

Why is the Paradigm Biopharmaceuticals Limited (PAR) stock price going up or down today?

The stock price of Paradigm Biopharmaceuticals Limited (PAR) can change with earnings, company news, and overall market sentiment. Paradigm Biopharmaceuticals Limited operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Paradigm Biopharmaceuticals Limited stock expensive at its current price?

Whether Paradigm Biopharmaceuticals Limited looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for PAR on this page is -2.24. EPS on this page is -0.09. Compare those figures with peers and growth expectations before deciding if the current Paradigm Biopharmaceuticals Limited price is justified.

How has the stock price of Paradigm Biopharmaceuticals Limited (PAR) performed historically?

Historical performance for Paradigm Biopharmaceuticals Limited (PAR) is shown on the price chart on this page. Review multi-period moves alongside volume to see how PAR reacted to past earnings and market events.

Should I buy Paradigm Biopharmaceuticals Limited (PAR) stock, at this price?

Buying Paradigm Biopharmaceuticals Limited (PAR) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.